ESMO is pleased to present a new ESMO Patient Guide in Hepatocellular Carcinoma, an important new edition in our Patient Guide Series.

Reflecting key developments in the field, this new ESMO Patient Guide in Hepatocellular Carcinoma delivers the following new information compared to the previous edition:

  • Information on the physiological role of the liver
  • Text on shared decision-making
  • Details on the BCLC staging system
  • Treatment options updated to align with the latest ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of hepatocellular carcinoma
  • Text on clinical trials, including immunotherapy
  • Section on supportive interventions, including palliative, end-of-life and survivorship care
  • Table summarising the important side effects of targeted therapies
  • Section on the importance of a healthy lifestyle and exercise
  • Section on the long-term effects of treatment
  • Section on emotional support and support groups

The previous edition of this guide was translated into 11 languages through the kind support of national medical associations and patient advocacy organisations. The availability of translations in languages spoken across continents ensured the guide was well received in many countries worldwide. We welcome support for the translation and dissemination of this new and updated version. To express an interest in providing a translation, please contact

This guide has been developed and reviewed by an editorial board composed of:

  • Representatives of the European Society for Medical Oncology (ESMO): Erika Martinelli; Claire Bramley; Svetlana Jezdic; and Jean-Yves Douillard
  • Representatives of the European Liver Patients’ Association (ELPA): Teresa Casanovas Taltavull, Marko Korenjak

ESMO Patient Guides in other topics are available here. The medical information in all of our Patient Guides is based on the ESMO Clinical Practice Guidelines.